CClinicalTrials.gg
Not yet recruitingNCT07694518Updated Jul 13, 2026

Role of Endoscopic Third Ventriculostomy Imanagement of Hydrocephalus in Pediatric Age Group; Clinical and Surgical Outcome

An interventional study of Fenestration of the floor of the third ventricle and Endoscopic third ventriculostomy of the brain third ventricle in Hydrocephalus, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
6 Months to 18 Years
Sex
All
01

Study summary

Endoscopic third ventriculostomy in cases of hydrocephalus provide less invasive and safe technique than ventriculoperitoneal Shunt also decrease complications of ventriculoperitoneal Shunt

Read the detailed description

Endoscopic third ventriculostomy (ETV) is a minimally invasive neurosurgical procedure used to treat obstructive hydrocephalus in children. By creating an opening in the floor of the third ventricle, the surgeon establishes a new pathway for cerebrospinal fluid (CSF) to bypass the blockage and drain naturally, potentially eliminating the need for a traditional brain shunt.

02

Conditions studied

  • Hydrocephalus

Browse trials for

03

In context

Hydrocephalus

210 studies on the registry are indexed under Hydrocephalus; 51 are open to participants now.

This study's planned enrollment of 30 is below the median of 50 across 105 interventional studies indexed under Hydrocephalus.

Browse Hydrocephalus studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • cases hydrocephalus diagnosed by CT or MRI.in pediatric age group up to 18 years
  • Both sex (males and females) will be included.

Exclusion criteria

Exclusion Criteria:

  • cases with hydrocephalus associated with csf infection or hemorrhage
  • Previously operated VP shunt or ETV .
  • Mult cystic hydrocephalus
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Hydrocephalus in pediatric age group

    Endoscopic third ventriculostomy in cases with hydrocephalus in pediatric age group

    Procedure: Fenestration of the floor of the third ventricle · Procedure: Endoscopic third ventriculostomy of the brain third ventricle · Procedure: Endoscopic third ventriculostomy

Interventions

  • ProcedureFenestration of the floor of the third ventricle

    Endoscopic third ventriculostomy of the third ventricle of the brain

  • ProcedureEndoscopic third ventriculostomy of the brain third ventricle

    Surgeons insert a rigid endoscope through a small burr hole in the skull into the ventricular system. They use a catheter or laser to puncture a tiny, precise opening in the floor of the third ventricle

  • ProcedureEndoscopic third ventriculostomy

    Surgeons insert a rigid endoscope through a small burr hole in the skull into the ventricular system. They use a catheter or laser to puncture a tiny, precise opening in the floor of the third ventricle

06

What researchers measure

Primary outcomes

  1. Changes in manifestation according to ETVSS endoscopic third ventriculostomy success score with assement of level of consciousness degree of papiledema and severity of headache

    ETVSS ETV success score is predictive tool used to estimate ETV success based on factors like age etiology previous shunt other pathologies The score is expressed as a number from 0 to 90 with assement of level of consciousness degree of papiledema and severity of headache Score 70 indicate an estimated 70 % chance of success

    Time frame: 6 month

07

Study locations

1 site
  • Sohag University
    Sohag, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07694518
Lead sponsor
Sohag University
Responsible party
Ahmed Ismael Marzouk (Principal investigator, Sohag University) — Principal investigator
First posted
Jul 10, 2026
Start date
Jul 12, 2026 (estimated)
Primary completion
Aug 14, 2026 (estimated)
Completion
Dec 24, 2026 (estimated)
Last update
Jul 13, 2026

Study contacts

Ahmed Esmael Marzouk, Resident
Contact
ahmed.esmael@med.sohag.edu.eg
201156294688 ext. 201004213207

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion